•
Jun 30, 2024

Bruker Q2 2024 Earnings Report

Bruker's Q2 2024 financial results were released, showing revenue growth and strategic acquisitions.

Key Takeaways

Bruker reported strong Q2 2024 results with revenues of $800.7 million, up 17.4% year-over-year, and organic revenue growth of 7.4%. The company's non-GAAP EPS increased by 4.0% to $0.52. Bruker has increased its full-year revenue guidance to $3.38-$3.44 billion, which now includes the NanoString business.

Q2 2024 revenues reached $800.7 million, a 17.4% increase year-over-year.

Organic revenue grew by 7.4% year-over-year.

GAAP EPS was $0.05, while non-GAAP EPS was $0.52, up 4.0% year-over-year.

Full-year 2024 revenue guidance increased to $3.38-$3.44 billion, including the NanoString business.

Total Revenue
$801M
Previous year: $682M
+17.4%
EPS
$0.52
Previous year: $0.5
+4.0%
Organic Revenue Growth
7.4%
Previous year: 13.5%
-45.2%
Non-GAAP Operating Margin
13.8%
Previous year: 15.3%
-9.8%
Gross Profit
$390M
Previous year: $341M
+14.4%
Cash and Equivalents
$170M
Previous year: $575M
-70.5%
Free Cash Flow
-$25.1M
Previous year: -$10.5M
+139.0%
Total Assets
$5.9B
Previous year: $3.86B
+53.0%

Bruker

Bruker

Forward Guidance

Bruker now expects FY 2024 revenues of $3.38 to $3.44 billion, with 14% to 16% year-over-year reported revenue growth. Bruker now expects FY 2024 non-GAAP EPS of $2.59 to $2.64.

Positive Outlook

  • Organic revenue growth of 5% to 7%.
  • M&A tailwind of approximately 10%.
  • CER revenue growth of 15% to 17%.
  • Revenue between $3.38 to $3.44 billion
  • Non-GAAP EPS of $2.59 to $2.64

Challenges Ahead

  • A foreign currency translation revenue headwind of approximately -1%.
  • Impact of supply chain challenges, including inflationary pressures
  • Impact of geopolitical tensions and any sanctions
  • Conflict in Israel, Palestine and surrounding areas
  • Ongoing tensions between the United States and China